Curanex Pharmaceuticals (CURX) Cash & Equivalents (2024 - 2025)
Curanex Pharmaceuticals' (CURX) quarterly Cash & Equivalents came in at $5.0 million in Q4 2025, up 3240.12% YoY from $148891.0 in Q4 2024, and down 14.71% on a QoQ basis from $5.8 million in Q3 2025.
Curanex Pharmaceuticals (CURX) Cash & Equivalents (2024 - 2025) Analysis & Trends
Curanex Pharmaceuticals (CURX) has 2 years of Cash & Equivalents data on file, last reported at $5.0 million in Q4 2025.
- Quarterly Cash & Equivalents rose 3240.12% year-over-year to $5.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.0 million (up 3240.12% YoY) and the FY2025 annual result came in at $5.0 million, up 3240.12% from the prior year.
- Cash & Equivalents slipped to $5.0 million in Q4 2025, from $5.8 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $5.8 million in Q3 2025 to a low of $108862.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | Curanex Pharmaceuticals | 6.02 Mn | 1.02 Mn | - | 5.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.97 Mn |
| Sep 30, 2025 | 5.83 Mn |
| Jun 30, 2025 | 108,862.00 |
| Dec 31, 2024 | 148,891.00 |
| Sep 30, 2024 | 244,317.00 |